Study of Lymphoma in Asia
- Lymphoma rates in Asia have been lower than in the West, but rates have been rising in recent years. Most studies of lymphoma patients have been conducted in the West. Less information is available about the factors that might contribute to the rise of lymphoma in Asia. Researchers want to collect medical and personal histories and samples from people who have recently been diagnosed with lymphoma. This information will help them study possible reasons for this increase.
- To collect samples and histories as part of an introductory study of lymphoma in Asia.
- People between 18 and 79 years of age who have entered study hospitals in Hong Kong, Taiwan, and mainland China for treatment for any type of lymphoma.
- Healthy volunteers between 18 and 79 who have never had lymphoma.
- Participants will be screened with a physical exam and medical history.
- They will provide blood samples and cheek cell samples for testing.
- Participants will complete a questionnaire about their personal health history. They will answer questions about exposures to chemicals like pesticides. They will also be asked about family medical history and work and residential history. Finally they will answer questions about lifestyle factors like diet and exercise.
- They will give permission for the researchers to see their medical records. Researchers will also have access to any tumor samples collected as part of treatment.
|Study Design:||Time Perspective: Retrospective|
|Official Title:||A Multi-Center International Hospital-Based Case-Control Study of Lymphoma in Asia (AsiaLymph)|
- Evaluation of chemical exposures and genetic susceptibility [ Time Frame: 2020 ]
- Explore relationship between other factors (viral infections, UV exposure, medical conditions, and lifestyle factors and non-Hodgkin Lymphoma [ Time Frame: 2020 ]
|Study Start Date:||July 2011|
The contribution of environmental, occupational and genetic factors to lymphoma has generated a series of novel findings in studies of Caucasians. However, none of the chemical associations have been conclusively established and the identification of the key, functional alleles in gene regions associated with risk of NHL requires further elucidation. Further, the ability to follow-up, confirm, and extend these observations is limited by the low prevalence and limited range of several important chemical exposures and the high to complete linkage disequilibrium among key candidate genetic loci in Western populations. To optimize the ability to build on and clarify these findings, it is necessary to investigate populations that differ from Caucasians in both exposure patterns and underlying genetic structure. A multidisciplinary case-control study of lymphoma in Asia provides an opportunity to replicate and extend recent and novel observations made in studies among Caucasians in a population that is distinctly different with regard to patterns of key risk factors, including range of exposures, prevalence of exposures, correlations between exposures, and variation in gene regions of particular interest. Thus, a hospital-based case-control study of lymphoma in Eastern Asia (i.e., AsiaLymph) of 4,200 cases and 4,200 controls to be enrolled over a three-year period will be conducted. The major postulated risk factors for evaluation in this study are chemical exposures (i.e., organochlorines, trichloroethylene, and benzene) and genetic susceptibility. Other factors potentially related to NHL and leukemia, such as viral infections, UV exposure, medical conditions, and other lifestyle factors will also be explored. A particularly noteworthy aspect of AsiaLymph is central pathology review with immunophenotyping by two of the world s leading lymphoma pathologists, which will enable accurate analysis of findings by molecular and histologic subtypes. AsiaLymph represents the optimal next step in the DCEG lymphoma portfolio. AsiaLymph should confirm and extend previous findings, and yield novel insights into the causes of lymphoma in both Asia and the West.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01584141
|Contact: Qing Lan, M.D.||(301) email@example.com|
|Tianjin Medical University Cancer Institute & Hospital||Recruiting|
|Hexi District, China, 300060|
|University of Hong Kong||Recruiting|
|Pokfulam, Hong Kong|
|Buddhis Dalin Tzu Chi General Hospital||Recruiting|
|Dalin Town, Taiwan|
|Principal Investigator:||Qing Lan, M.D.||National Cancer Institute (NCI)|